Acid-base balance: the bicarbonate buffer system, respiratory and metabolic compensation

Intuition Beginner

Blood pH must stay near 7.40 for enzymes, ion channels, and cellular processes to work correctly. Even a shift of 0.1 pH unit in either direction disrupts protein structure and electrical signalling. The body defends this narrow range with three lines of defence.

The first line is chemical buffers -- molecules that can soak up or release hydrogen ions on the spot. The most important buffer in the blood is the bicarbonate buffer system: carbon dioxide reacts with water to form carbonic acid, which dissociates into hydrogen ions and bicarbonate. When excess acid accumulates, bicarbonate binds the extra hydrogen ions. When excess base accumulates, carbonic acid releases hydrogen ions to counteract it.

The second line is respiratory compensation. Because carbon dioxide is an acid precursor (CO2 + H2O yields H+), the lungs can adjust blood pH by changing how fast and how deeply you breathe. If the blood becomes too acidic, the respiratory centre in the brainstem increases ventilation, blowing off CO2 and raising pH. This response begins within minutes.

The third line is renal compensation. The kidneys can excrete acid (as hydrogen ions and ammonium) and reabsorb or generate new bicarbonate. If the blood is too acidic, the kidneys excrete more acid and retain more bicarbonate. If the blood is too alkaline, they do the reverse. Renal compensation is slower than respiratory compensation (hours to days) but is more powerful and sustained.

When these mechanisms fail or are overwhelmed, acid-base disorders result. Acidosis means the blood is too acidic (pH below 7.35). Alkalosis means the blood is too alkaline (pH above 7.45). Each disorder can have a respiratory cause (too much or too little CO2) or a metabolic cause (abnormal bicarbonate from kidney dysfunction, loss of stomach acid, or accumulation of metabolic acids). The body compensates: a respiratory disorder triggers metabolic compensation (via the kidneys) and a metabolic disorder triggers respiratory compensation (via the lungs).

Visual Beginner

The diagram shows how CO2, bicarbonate, and hydrogen ions are connected through a single equilibrium. Disturbing any one component shifts the entire system. The lungs regulate the CO2 side; the kidneys regulate the bicarbonate side. Together they hold pH at 7.40.

Worked example Beginner

Calculate blood pH from the Henderson-Hasselbalch equation using typical arterial values.

Given: arterial PCO2 = 40 mmHg, [HCO3-] = 24 mEq/L, pKa of the bicarbonate system = 6.1, solubility coefficient for CO2 = 0.03 mEq/L per mmHg.

Step 1. Calculate the dissolved CO2 concentration:

$$[{\text{dissolved CO}}_2]=0.03\times P_{C{O}_2}=0.03\times 40=1.2\text{ mEq/L}.$$

Step 2. Apply the Henderson-Hasselbalch equation:

$$\text{pH}=\text{pKa}+\log \left(\frac{[{\text{HCO}}_3^{-}]}{[{\text{dissolved CO}}_2]}\right)=6.1+\log \left(\frac{24}{1.2}\right)=6.1+\log (20).$$

Step 3. Evaluate:

$$\log (20)\approx 1.30,\text{pH}=6.1+1.30=\mathrm{7.40.}$$

Normal arterial blood pH is 7.40. The ratio [HCO3-]/[dissolved CO2] = 24/1.2 = 20:1 produces this pH. Any factor that changes this ratio -- increasing CO2, decreasing bicarbonate, or both -- will lower pH (acidosis). Any factor that decreases CO2 or increases bicarbonate will raise pH (alkalosis).

Check your understanding Beginner

Formal definition Intermediate+

The Henderson-Hasselbalch equation

The bicarbonate buffer system is described by the equilibrium:

$${\text{CO}}_2+{\text{H}}_2\text{O}\rightleftharpoons {\text{H}}_2{\text{CO}}_3\rightleftharpoons {\text{H}}^{+}+{\text{HCO}}_3^{-}.$$

The Henderson-Hasselbalch equation relates blood pH to the bicarbonate-to-CO2 ratio:

$$\text{pH}=\text{pKa}+\log \left(\frac{[{\text{HCO}}_3^{-}]}{\alpha \times P_{C{O}_2}}\right),$$

where pKa = 6.1 (for the bicarbonate system at 37 degrees C), $\alpha$ = 0.03 mEq/L/mmHg is the solubility coefficient of CO2 in plasma, and PCO2 is the partial pressure of CO2 in arterial blood. Normal values: [HCO3-] = 24 mEq/L, PCO2 = 40 mmHg, pH = 7.40.

The equation reveals that pH depends not on the absolute concentrations of HCO3- and CO2, but on their ratio. Doubling both HCO3- and CO2 leaves pH unchanged. A change in either variable alone shifts pH.

The three lines of defence against pH disturbance

1. Chemical buffers (seconds to minutes). The immediate defence is provided by buffer systems that resist pH change by binding or releasing H+. The major extracellular buffer is bicarbonate (CO2/HCO3-). Intracellular buffers include haemoglobin (the most important blood buffer for CO2-generated acid), organic phosphates, and proteins. Bone contributes a large but slowly mobilisable buffer pool (alkali salts of calcium phosphate). Buffers do not eliminate acid or base from the body; they minimise the pH change until the second and third lines of defence can restore balance.

2. Respiratory compensation (minutes to hours). The respiratory centre in the medulla oblongata responds to changes in arterial pH and PCO2 via central chemoreceptors (sensing CSF pH, which reflects arterial PCO2) and peripheral chemoreceptors in the carotid and aortic bodies (sensing arterial pH and PO2). A decrease in pH (metabolic acidosis) stimulates ventilation, lowering PCO2 and raising pH back toward normal. An increase in pH (metabolic alkalosis) suppresses ventilation, allowing PCO2 to rise and lowering pH back toward normal. Respiratory compensation is rapid but incomplete: it cannot fully correct pH because the ventilatory response itself alters PCO2, which feeds back on the respiratory drive.

3. Renal compensation (hours to days). The kidneys regulate blood pH by three mechanisms:

• Bicarbonate reabsorption: The proximal tubule reabsorbs 80-90% of filtered HCO3- via apical Na+/H+ exchange (NHE3), intracellular carbonic anhydrase (CA-II), and basolateral Na+/HCO3-/CO3(2-) cotransport (NBCe1). Secreted H+ combines with filtered HCO3- in the lumen to form CO2 and H2O (catalysed by apical CA-IV); CO2 diffuses back into the cell and is rehydrated to generate new H+ and HCO3-.
• Titratable acid excretion: H+ that does not combine with filtered bicarbonate is buffered by urinary phosphate (HPO4(2-) + H+ -> H2PO4-) and excreted. Each mole of titratable acid excreted generates one mole of new HCO3- returned to the blood.
• Ammonium excretion: Proximal tubule cells metabolise glutamine to produce NH4+ and HCO3-. NH4+ is secreted into the lumen (via NHE3 substituting NH4+ for H+) and excreted. Each mole of NH4+ excreted generates one mole of new HCO3-. In chronic metabolic acidosis, ammonium excretion increases up to tenfold, making it the most important renal compensatory mechanism.

The four primary acid-base disorders

Disorder	Primary change	pH	Compensation
Respiratory acidosis	PCO2 increased (hypoventilation)	Decreased	Kidneys increase HCO3- reabsorption and NH4+ excretion
Respiratory alkalosis	PCO2 decreased (hyperventilation)	Increased	Kidneys decrease HCO3- reabsorption, excrete HCO3-
Metabolic acidosis	HCO3- decreased (acid accumulation or bicarbonate loss)	Decreased	Lungs increase ventilation (Kussmaul breathing), lowering PCO2
Metabolic alkalosis	HCO3- increased (base excess or acid loss)	Increased	Lungs decrease ventilation, allowing PCO2 to rise

Respiratory compensation for metabolic disorders begins within minutes and reaches a new steady state in 12-24 hours. Renal compensation for respiratory disorders begins within hours and reaches maximum effect in 3-5 days. This time course difference means that acid-base disturbances can be classified as acute (no compensation yet), partially compensated, or fully compensated.

The anion gap

The anion gap (AG) is the difference between the major measured cations and the major measured anions in serum:

$$\text{AG}=[{\text{Na}}^{+}]-([{\text{Cl}}^{-}]+[{\text{HCO}}_3^{-}]).$$

Normal anion gap = 12 +/- 4 mEq/L (the "gap" represents unmeasured anions: albumin, phosphate, sulphate, organic acids). The anion gap distinguishes two categories of metabolic acidosis:

• High-anion-gap metabolic acidosis (HAGMA): an unmeasured acid has accumulated, consuming bicarbonate and adding an unmeasured anion. Causes include lactic acidosis, diabetic ketoacidosis (beta-hydroxybutyrate, acetoacetate), renal failure (sulphate, phosphate, organic acids), methanol (formate), ethylene glycol (oxalate), and salicylate.
• Normal-anion-gap (hyperchloraemic) metabolic acidosis: bicarbonate is lost and replaced by chloride, so the anion gap does not change. Causes include diarrhoea (GI bicarbonate loss), renal tubular acidosis (impaired HCO3- reabsorption or H+ secretion), carbonic anhydrase inhibitors, and ureteral diversions.

The anion gap must be corrected for albumin: every 1 g/dL decrease in albumin from the normal value of 4 g/dL lowers the expected anion gap by approximately 2.5 mEq/L. A "normal" anion gap of 12 in a patient with albumin of 2 g/dL is actually elevated (corrected AG = 12 + 2.5 x 2 = 17).

The Davenport diagram

The Davenport diagram plots plasma [HCO3-] on the y-axis against pH on the x-axis. On this diagram:

• The buffer line is a nearly linear relationship between pH and [HCO3-] for whole blood (slope determined by haemoglobin buffering of CO2). Moving along the buffer line represents a pure respiratory change (increasing or decreasing PCO2 shifts the equilibrium along the buffer line).
• The bicarbonate isobar is a curved line representing the Henderson-Hasselbalch relationship for a given PCO2. Each isobar is a hyperbola: [HCO3-] is high at high pH and low at low pH for any fixed PCO2.
• Respiratory acidosis moves the operating point up and left along the buffer line (increased PCO2, decreased pH, increased [HCO3-] due to buffering).
• Metabolic acidosis moves the operating point down and left at constant PCO2 (decreased [HCO3-], decreased pH).

The Davenport diagram is the standard graphical tool for visualising acid-base disturbances and their compensations, allowing the clinician to identify the primary disorder and the degree of compensation from a single arterial blood gas (ABG) measurement.

Clinical approach to ABG interpretation

A systematic approach to arterial blood gas interpretation:

1. Assess pH: acidosis (< 7.35), normal (7.35-7.45), or alkalosis (> 7.45).
2. Identify the primary disorder: compare PCO2 and HCO3- to determine whether the respiratory or metabolic component matches the pH direction. If PCO2 is high and pH is low, the primary disorder is respiratory acidosis. If HCO3- is low and pH is low, the primary disorder is metabolic acidosis.
3. Assess compensation: calculate the expected compensation using standard formulas and compare to the measured values:
   • Metabolic acidosis: expected PCO2 = 1.5 x [HCO3-] + 8 +/- 2 (Winter's formula).
   • Metabolic alkalosis: expected PCO2 = 0.7 x [HCO3-] + 21 +/- 2.
   • Acute respiratory acidosis: [HCO3-] increases by 1 mEq/L for every 10 mmHg rise in PCO2.
   • Chronic respiratory acidosis: [HCO3-] increases by 3.5 mEq/L for every 10 mmHg rise in PCO2.
   • Acute respiratory alkalosis: [HCO3-] decreases by 2 mEq/L for every 10 mmHg drop in PCO2.
   • Chronic respiratory alkalosis: [HCO3-] decreases by 4 mEq/L for every 10 mmHg drop in PCO2.
4. Calculate the anion gap and, if elevated, the delta-delta ratio.
5. Correlate with the clinical context: the numbers must be interpreted in light of the patient's history, medications, and other laboratory values.

Key theorem with proof Intermediate+

Theorem (Compensation predictability). For each of the four primary acid-base disorders, the compensatory response follows a predictable quantitative relationship. The expected compensatory change can be calculated from the degree of primary disturbance, and deviation from the expected compensation indicates the presence of a second (mixed) acid-base disorder.

Proof. Consider metabolic acidosis as the paradigmatic case. A decrease in [HCO3-] lowers blood pH, which is detected by peripheral chemoreceptors. The respiratory centre responds by increasing alveolar ventilation, lowering PCO2. The relationship between the degree of metabolic acidosis and the expected respiratory compensation was established empirically by Winter et al. (1967):

$$P_{C{O}_2}^{\text{expected}}=1.5\times [{\text{HCO}}_3^{-}]+8\pm 2.$$

This linear relationship arises from the properties of the chemoreceptor feedback system. The peripheral chemoreceptors respond to the change in pH proportional to the change in [H+], which is itself determined by the Henderson-Hasselbalch equation. The respiratory centre increases ventilation approximately linearly with the decrease in pH (in the physiological range), and the resulting change in PCO2 depends on the relationship between alveolar ventilation and CO2 elimination:

$$P_{C{O}_2}=\frac{V_{C{O}_2}\times k}{V_A},$$

where $V_{C{O}_2}$ is CO2 production, $V_A$ is alveolar ventilation, and $k$ is a constant. As $V_A$ increases in response to acidosis, $P_{C{O}_2}$ decreases. The proportionality constant of 1.5 in Winter's formula reflects the integrated gain of the chemoreceptor-to-ventilation feedback loop.

If the measured PCO2 deviates from the expected value by more than the confidence interval (+/- 2 mmHg), a second acid-base disorder is present. A measured PCO2 higher than expected indicates an additional respiratory acidosis; a measured PCO2 lower than expected indicates an additional respiratory alkalosis.

Analogous arguments establish the compensation rules for the other three primary disorders. For chronic respiratory acidosis, the renal compensation increases [HCO3-] by approximately 3.5 mEq/L per 10 mmHg increase in PCO2, reflecting the time-dependent upregulation of proximal tubular ammonium excretion and bicarbonate reabsorption. For acute respiratory acidosis, compensation is limited to the buffering effect of haemoglobin and other non-bicarbonate buffers (approximately 1 mEq/L increase in [HCO3-] per 10 mmHg rise in PCO2), because renal compensation has not yet had time to develop. $\square$

Bridge. This compensation theorem builds on the renal transport mechanisms described in 18.08.02 pending, specifically the nephron's ability to adjust bicarbonate reabsorption (via NHE3 and carbonic anhydrase in the proximal tubule), titratable acid excretion, and ammonium excretion. The time course of renal compensation (hours to days) reflects the time required to upregulate proximal tubular glutamine metabolism and ammonium synthesis.

Exercises Intermediate+

Mixed acid-base disorders, the Stewart approach, and clinical acid-base pathology Master

Mixed acid-base disorders

Mixed acid-base disorders occur when two or more primary disorders are present simultaneously. They are identified when the measured compensation deviates from the expected compensation for a single disorder. Common mixed disorders include:

• Metabolic acidosis + respiratory alkalosis: pH may be near normal, but PCO2 is lower than expected for the degree of metabolic acidosis and [HCO3-] is lower than expected for the degree of respiratory alkalosis. Classic scenario: salicylate intoxication (salicylates directly stimulate ventilation causing respiratory alkalosis, and at higher doses cause metabolic acidosis from uncoupled oxidative phosphorylation and lactate accumulation).
• Metabolic acidosis + metabolic alkalosis: the anion gap is elevated but the delta AG exceeds the delta [HCO3-] (see delta-delta below). Classic scenario: a patient with diabetic ketoacidosis (HAGMA) who is also vomiting (metabolic alkalosis from gastric acid loss).
• Respiratory acidosis + metabolic alkalosis: the most common mixed disorder in hospitalised patients. Classic scenario: a patient with COPD (chronic respiratory acidosis) receiving diuretics (metabolic alkalosis from volume contraction and hypochloraemia).
• Respiratory acidosis + metabolic acidosis: very low pH, high PCO2, low [HCO3-]. Classic scenario: cardiac arrest (lactic acidosis from tissue hypoperfusion + respiratory acidosis from hypoventilation).

The delta-delta (delta ratio)

The delta-delta compares the change in anion gap to the change in bicarbonate to detect a mixed metabolic disorder:

$$\Delta \text{-}\Delta =\frac{\Delta \text{AG}}{\Delta [{\text{HCO}}_3^{-}]}=\frac{{\text{AG}}_{\text{measured}}-{\text{AG}}_{\text{normal}}}{[{\text{HCO}}_3^{-}{]}_{\text{normal}}-[{\text{HCO}}_3^{-}{]}_{\text{measured}}}.$$

Using AG_normal = 12 and [HCO3-]_normal = 24:

• Delta-delta = 1-2: pure high-anion-gap metabolic acidosis. Each unmeasured anion that appears consumes one bicarbonate, so the rise in AG matches the fall in [HCO3-].
• Delta-delta > 2: concurrent metabolic alkalosis (or a concurrent normal-anion-gap process that is raising bicarbonate). The AG has risen more than [HCO3-] has fallen, indicating bicarbonate was also added from a second process.
• Delta-delta < 1: concurrent normal-anion-gap (hyperchloraemic) metabolic acidosis. The [HCO3-] has fallen more than the AG has risen, indicating bicarbonate is also being lost through a non-anion-gap mechanism.

The Stewart approach (strong ion difference)

Peter Stewart (1981) proposed an alternative framework for acid-base analysis based on physical chemistry rather than the bicarbonate-centred model. Stewart's approach identifies three independent variables that determine the pH of a body fluid:

1. Strong ion difference (SID): the difference between the sums of fully dissociated (strong) cations and anions. In plasma, SID = ([Na+] + [K+] + [Ca2+] + [Mg2+]) - ([Cl-] + [other strong anions]). The apparent SID (SIDa) is approximately 40 mEq/L. An increase in SID (e.g., from loss of Cl- by vomiting) raises pH. A decrease in SID (e.g., from accumulation of lactate or other strong anions) lowers pH.
2. PCO2: the total concentration of weak acid (primarily albumin and phosphate). A decrease in albumin (e.g., in critical illness) causes a metabolic alkalosis in the Stewart framework because fewer weak acids are available to dissociate and contribute H+.

The Stewart approach explains several clinical observations that are awkward in the bicarbonate-centred model: why normal saline (NaCl in water, SID = 0) causes a hyperchloraemic metabolic acidosis (the excess Cl- lowers SID), why hypoalbuminaemia causes a metabolic alkalosis, and why the "anion gap" is better understood as the gap between measured and unmeasured strong ions plus weak acids.

The Stewart and bicarbonate-centred approaches are mathematically equivalent (they are derived from the same physical chemistry), but the Stewart approach provides mechanistic insight into how fluid and electrolyte therapy alter acid-base status.

Lactic acidosis (type A vs type B)

Lactic acidosis (blood lactate > 4 mmol/L) is the most common cause of high-anion-gap metabolic acidosis in hospitalised patients. It is divided into two types:

Type A lactic acidosis results from tissue hypoxia and impaired oxidative phosphorylation. Causes include haemorrhagic shock, septic shock, cardiogenic shock, mesenteric ischaemia, carbon monoxide poisoning, and severe anaemia. In tissue hypoxia, pyruvate cannot enter the Krebs cycle (which requires O2) and is instead reduced to lactate by lactate dehydrogenase, regenerating NAD+ to sustain glycolysis. The lactate anion contributes to the elevated anion gap.

Type B lactic acidosis occurs without clinical evidence of tissue hypoxia. Subtypes include:

• Type B1 (underlying disease): liver failure (impaired lactate clearance), diabetes mellitus, thiamine deficiency (pyruvate cannot enter the Krebs cycle), leukaemia/lymphoma (high tumour glycolytic rate).
• Type B2 (drugs/toxins): metformin (inhibits mitochondrial complex I, especially in renal impairment), linezolid, propofol infusion syndrome, nucleoside reverse transcriptase inhibitors (mitochondrial toxicity), and cyanide (blocks cytochrome c oxidase).
• Type B3 (inborn errors of metabolism): mitochondrial myopathies, pyruvate dehydrogenase deficiency, fatty acid oxidation defects.

The mortality of lactic acidosis is determined by the underlying cause, not the lactate level itself. Treatment of type A lactic acidosis requires addressing the underlying cause of tissue hypoxia (fluid resuscitation, inotropes, source control in sepsis). Sodium bicarbonate therapy is controversial and generally reserved for pH < 7.10 with haemodynamic instability, because bicarbonate administration generates CO2 (which can worsen intracellular acidosis) and may paradoxically lower CSF pH.

Diabetic ketoacidosis (DKA)

DKA is a life-threatening complication of type 1 (and occasionally type 2) diabetes mellitus caused by absolute or relative insulin deficiency combined with counter-regulatory hormone excess (glucagon, cortisol, catecholamines, growth hormone). The pathophysiology involves:

1. Insulin deficiency removes the inhibition of hormone-sensitive lipase in adipose tissue, causing uncontrolled lipolysis and release of free fatty acids into the circulation.
2. Free fatty acids are taken up by the liver and oxidised in mitochondria to acetyl-CoA. When the Krebs cycle is saturated, acetyl-CoA is diverted to ketone body production: acetoacetate and beta-hydroxybutyrate (the ratio depends on the mitochondrial NAD+/NADH redox state).
3. Ketone bodies are strong acids that dissociate to release H+, consuming bicarbonate and producing a high-anion-gap metabolic acidosis.
4. Hyperglycaemia from insulin deficiency causes osmotic diuresis (glucose exceeds the renal threshold, pulling water and electrolytes with it), producing volume depletion, hypokalaemia (total body potassium is depleted despite normal or elevated serum potassium due to the acidosis-induced potassium shift), and progressive haemodynamic compromise.

ABG in DKA shows metabolic acidosis (pH 6.9-7.30, [HCO3-] often < 10 mEq/L, elevated AG) with respiratory compensation (PCO2 low by Winter's formula). The anion gap may be lower than expected if the patient has also lost bicarbonate from vomiting or osmotic diuresis. Serum ketones measured by the nitroprusside test detect acetoacetate and acetone but not beta-hydroxybutyrate, which is the predominant ketone in DKA; direct measurement of beta-hydroxybutyrate is therefore preferred.

Management follows a protocol: (1) volume resuscitation with normal saline (1-1.5 L in the first hour), (2) continuous insulin infusion (0.1 units/kg/hr) to suppress ketogenesis, (3) potassium replacement (hypokalaemia is unmasked as insulin drives potassium into cells and acidosis corrects), (4) monitoring of glucose, electrolytes, and anion gap hourly, and (5) switching to D5W (5% dextrose in water) with insulin when glucose falls below 200-250 mg/dL to prevent hypoglycaemia while continuing to suppress ketogenesis. Bicarbonate is generally not given unless pH < 6.9.

Renal tubular acidosis (RTA)

Renal tubular acidosis comprises a group of disorders in which the kidneys fail to excrete sufficient acid or reabsorb sufficient bicarbonate despite normal GFR. Three major types are recognised:

Type 1 (distal) RTA results from impaired H+ secretion in the alpha-intercalated cells of the collecting duct. The defect may be in the H+-ATPase pump itself or in the apical membrane's impermeability to H+ back-leak. Urine pH cannot be lowered below 5.3 (normally, urine pH can fall to 4.5). Consequences include hypokalaemic hyperchloraemic metabolic acidosis (normal anion gap), nephrocalcinosis and nephrolithiasis (alkaline urine with hypercalciuria and low citrate), and bone disease (buffering of chronic acidosis by bone alkali release). Causes include autoimmune diseases (Sjogren's syndrome, SLE), amphotericin B (creates a membrane channel for H+ back-leak), and genetic mutations in the H+-ATPase or AE1 (band 3) transporter.

Type 2 (proximal) RTA results from impaired HCO3- reabsorption in the proximal tubule. The proximal tubule normally reabsorbs 80-90% of filtered HCO3-; in type 2 RTA, the threshold for bicarbonate reabsorption is reduced, and bicarbonate is wasted until plasma [HCO3-] falls to a level the defective proximal tubule can handle (typically 15-18 mEq/L). At that point, the distal nephron can reabsorb the remaining bicarbonate, and the acidosis stabilises. Urine pH is variable: high during bicarbonate wasting, low once the serum bicarbonate has fallen to the new threshold. Type 2 RTA is almost always accompanied by other proximal tubule defects (Fanconi syndrome: glycosuria, aminoaciduria, phosphaturia, uricosuria). Causes include cystinosis, multiple myeloma, tenofovir, and ifosfamide. Treatment requires large doses of oral bicarbonate (10-15 mEq/kg/day) because much of the administered bicarbonate is excreted.

Type 4 RTA results from aldosterone deficiency or aldosterone resistance in the collecting duct. Aldosterone stimulates ENaC-mediated sodium reabsorption, which creates the lumen-negative potential that drives both K+ secretion (via ROMK) and H+ secretion (via H+-ATPase). Without aldosterone action, the collecting duct retains potassium and fails to secrete H+, producing hyperkalaemic hyperchloraemic metabolic acidosis. This is the distinguishing feature: type 4 RTA is the only RTA with hyperkalaemia (types 1 and 2 cause hypokalaemia). Causes include hypoaldosteronism (primary adrenal insufficiency, hyporeninaemic hypoaldosteronism in diabetes mellitus), ACE inhibitors and ARBs (reduced angiotensin II and aldosterone), spironolactone and eplerenone (mineralocorticoid receptor blockade), NSAIDs (reduced renin), and calcineurin inhibitors (direct tubular toxicity). Treatment addresses the underlying cause and may include fludrocortisone (a synthetic mineralocorticoid) or alkali therapy.

Metabolic alkalosis

Metabolic alkalosis ([HCO3-] > 28 mEq/L, pH > 7.45) is generated by loss of H+ (vomiting, nasogastric suction) or gain of HCO3- (massive transfusion of citrate-buffered blood, oral bicarbonate ingestion) and is maintained by the kidney's inability to excrete the excess bicarbonate. The maintenance phase requires either volume depletion (which activates RAAS and increases proximal bicarbonate reabsorption), hypochloraemia (which reduces GFR and impairs bicarbonate excretion), or hypokalaemia (which increases proximal bicarbonate reabsorption and distal acid secretion).

Metabolic alkalosis is classified as chloride-responsive (urine Cl- < 10 mEq/L) or **chloride-resistant** (urine Cl- > 20 mEq/L):

• Chloride-responsive (the majority): vomiting, nasogastric suction, diuretic use, and contraction alkalosis. Treatment is volume and chloride repletion with normal saline (0.9% NaCl), which restores GFR and allows the kidney to excrete the excess bicarbonate.
• Chloride-resistant: primary hyperaldosteronism, Cushing's syndrome, Bartter syndrome, Gitelman syndrome, and exogenous alkali administration. Treatment targets the underlying cause (e.g., spironolactone for hyperaldosteronism).

Contraction alkalosis occurs when isotonic fluid loss (e.g., from diuretic therapy) reduces extracellular fluid volume while retaining bicarbonate. The bicarbonate originally dissolved in the lost fluid is concentrated in the smaller remaining extracellular space, raising [HCO3-]. The volume contraction also activates RAAS, which increases proximal bicarbonate reabsorption and distal acid secretion, perpetuating the alkalosis.

Toxic alcohols

Ingestion of ethylene glycol (antifreeze) or methanol (windshield washer fluid, industrial solvent) produces a high-anion-gap metabolic acidosis with potentially fatal consequences. Both alcohols are relatively non-toxic themselves but are metabolised by alcohol dehydrogenase (ADH) to highly toxic organic acids:

• Ethylene glycol is metabolised to glycolic acid and then oxalic acid. Oxalate binds calcium to form calcium oxalate crystals, which precipitate in the renal tubules causing acute kidney injury. Urinalysis shows envelope-shaped and needle-shaped calcium oxalate crystals. Clinical presentation includes early neurological symptoms (intoxication, ataxia), then cardiopulmonary depression, then renal failure (24-72 hours postingestion).
• Methanol is metabolised to formaldehyde and then formic acid. Formic acid causes retinal toxicity (visual disturbances, "snowstorm vision," blindness) and basal ganglia necrosis. Clinical presentation includes an apparent intoxication (without the smell of ethanol), visual symptoms, and abdominal pain.

Both toxicities are treated with fomepizole (an ADH inhibitor that blocks the first metabolic step) or intravenous ethanol (which competes for ADH because it has higher affinity), along with haemodialysis to remove the parent alcohol and toxic metabolites. The osmol gap (measured serum osmolality minus calculated osmolality) is elevated early in toxicity (before complete metabolism to organic acids narrows the anion gap).

Non-anion-gap (hyperchloraemic) metabolic acidosis

Non-anion-gap metabolic acidosis (NAGMA) occurs when bicarbonate is lost and replaced by chloride, so the anion gap does not change. The two broad categories are:

GI bicarbonate loss: diarrhoea (loss of bicarbonate-rich intestinal secretions), pancreatic fistulae, ureteral diversions (ileal conduits, where the bowel mucosa absorbs chloride in exchange for bicarbonate), and villous adenomas (secrete large volumes of bicarbonate-rich fluid).

Renal bicarbonate loss: renal tubular acidosis (types 1, 2, and 4, as described above), carbonic anhydrase inhibitors (acetazolamide impairs proximal bicarbonate reabsorption), and post-hypocapnic metabolic acidosis (prolonged hyperventilation causes renal bicarbonate wasting; when PCO2 is abruptly normalised, the depleted bicarbonate stores produce a transient NAGMA until the kidneys regenerate bicarbonate over 1-2 days).

Treatment of NAGMA is directed at the underlying cause. Potassium citrate or sodium citrate provides both alkali replacement and potassium supplementation in RTA.

Connections Master

• Renal physiology -- homeostasis 18.08.01 established the basic framework of renal acid-base regulation (bicarbonate reabsorption, titratable acid, ammonium excretion). This unit extends that framework into the integrated system of buffers, respiration, and renal compensation that maintains blood pH at 7.40 under physiological and pathological conditions.

• Nephron function 18.08.02 pending provides the segment-specific transport mechanisms that execute renal compensation: NHE3 and carbonic anhydrase in the proximal tubule for bicarbonate reabsorption, alpha-intercalated cells in the collecting duct for H+ secretion, and glutamine metabolism in the proximal tubule for ammonium generation. The time course of renal compensation (hours to days) reflects the time required to upregulate these specific transporters.

• Respiratory physiology 18.03.01 is directly connected because the lungs are the second line of defence in acid-base regulation. Alveolar ventilation determines PCO2, which is one of the two variables in the Henderson-Hasselbalch equation. Respiratory compensation for metabolic acidosis (Kussmaul breathing in DKA) and respiratory alkalosis at altitude are direct applications of the gas exchange principles covered in that unit.

• Endocrine hormones 18.07.01 regulate acid-base balance through aldosterone (which controls distal H+ secretion and potassium excretion in the collecting duct, linking potassium and acid-base homeostasis) and ADH (which influences renal ammonium excretion through effects on medullary recycling).

• Membrane transport 17.02.02 provides the molecular basis for every acid-base transport process in the nephron: NHE3 (Na+/H+ exchange), NBCe1 (Na+/HCO3- cotransport), H+-ATPase, AE1 (Cl-/HCO3- exchange), and carbonic anhydrase-catalysed hydration/dehydration reactions.

Historical & philosophical context Master

Lawrence Joseph Henderson (1908) ^{[Henderson 1908]} published the first quantitative treatment of the bicarbonate buffer system in blood, deriving the equation that relates pH to the ratio of bicarbonate to dissolved CO2. Henderson's work was rooted in his broader interest in the concept of "fitness of the environment" -- the idea that the chemical properties of water and carbon dioxide are uniquely suited to support life. The bicarbonate buffer system, which depends on the solubility of CO2 in water and the dissociation properties of carbonic acid, was a central example of this fitness.

Karl Hasselbalch (1916) adapted Henderson's equation into the logarithmic form now known as the Henderson-Hasselbalch equation, making it easier to use with pH measurements (the pH concept itself had been introduced by Sorensen in 1909). The equation became the cornerstone of clinical acid-base analysis and remains the primary tool for interpreting arterial blood gases.

The recognition that the body uses three distinct lines of defence (buffers, respiration, kidneys) operating at different speeds emerged from the work of multiple investigators in the early twentieth century. Walter Cannon (1926) coined the term "homeostasis" to describe this multi-layered regulatory architecture, and acid-base balance became one of its clearest illustrations.

The clinical approach to acid-base interpretation was systematised by Maxwell and Kleeman (1962) in Clinical Disorders of Fluid and Electrolyte Metabolism, and the compensation formulas (including Winter's formula for metabolic acidosis) were empirically derived from large datasets of arterial blood gas measurements in the 1960s and 1970s. The anion gap concept was introduced by Emmett and Narins (1977) as a clinical tool for differentiating causes of metabolic acidosis.

Peter Stewart (1981) ^{[Stewart 1981]} published How to Understand Acid-Base ^{[Stewart 1981 book]}, challenging the bicarbonate-centred paradigm with a quantitative physical chemistry approach based on strong ion difference. Stewart's framework was initially controversial but has gained acceptance in critical care medicine and anaesthesiology, where it explains acid-base changes associated with fluid resuscitation (normal saline-induced acidosis, "hyperchloraemia") more intuitively than the traditional approach. The mathematical equivalence of the Stewart and Henderson-Hasselbalch approaches was demonstrated by several groups in the 1990s, confirming that they describe the same underlying chemistry from different perspectives.

The Davenport diagram was introduced by Horace Davenport in his 1958 textbook The ABC of Acid-Base Chemistry ^{[Davenport 1958]}, providing a graphical method for visualising acid-base disturbances that remains in use today. Davenport's contribution was pedagogical rather than theoretical: he synthesised existing knowledge into an accessible visual format that allowed students and clinicians to reason about acid-base disturbances geometrically.

The treatment of diabetic ketoacidosis was revolutionised by the introduction of continuous insulin infusion protocols in the 1970s, which replaced bolus insulin therapy and dramatically reduced mortality. The protocolisation of DKA management (fluid resuscitation, insulin, potassium replacement, and careful monitoring) is one of the earliest examples of evidence-based protocolised critical care and set the template for later protocol-based approaches to sepsis and other emergencies.

Philosophically, acid-base balance illustrates the principle of nested homeostatic systems. The three lines of defence (buffers, respiration, kidneys) operate at different timescales and with different mechanisms, yet they all serve the same regulated variable (blood pH). The faster systems (chemical buffers) buy time for the slower but more powerful systems (renal compensation) to engage. This layered architecture ensures that pH is defended both acutely and chronically, and it explains why single-organ failure (e.g., renal failure) does not immediately cause fatal acidosis -- the remaining systems compensate until they too are overwhelmed.

Bibliography Master

1. Henderson, L. J., "The theory of neutrality regulation in the animal organism", Am. J. Physiol. 21 (1908), 427-448.

2. Hasselbalch, K. A., "Die Berechnung der Wasserstoffzahl des Blutes aus der freien und gebundenen Kohlensaeure desselben, und die Sauerstoffbindung des Blutes als Funktion der Wasserstoffzahl", Biochem. Z. 78 (1916), 112-144.

3. Sorensen, S. P. L., "Enzymstudien II: Ueber die Messung und die Bedeutung der Wasserstoffionenkonzentration bei enzymatischen Prozessen", Biochem. Z. 21 (1909), 131-304.

4. Cannon, W. B., "Organization for physiological homeostasis", Physiol. Rev. 9 (1929), 399-431.

5. Davenport, H. W., The ABC of Acid-Base Chemistry, 5th ed. (University of Chicago Press, 1969).

6. Stewart, P. A., "Independent and dependent variables of acid-base control", Respir. Physiol. 33 (1978), 9-26.

7. Stewart, P. A., How to Understand Acid-Base: A Quantitative Acid-Base Primer for Biology and Medicine (Elsevier, 1981).

8. Winter, S. D., Pearson, J. R., Gabow, P. A., Schultz, A. L. & Lepoff, R. B., "The fall of the serum anion gap", Arch. Intern. Med. 167 (1967), 1385-1392.

9. Emmett, M. & Narins, R. G., "Clinical use of the anion gap", Medicine 56 (1977), 38-54.

10. Guyton, A. C. & Hall, J. E., Textbook of Medical Physiology, 14th ed. (Elsevier, 2021), Ch. 32-33.

11. Sherwood, L., Human Physiology: From Cells to Systems, 9th ed. (Cengage, 2016), Ch. 15.

12. Silverthorn, D. U., Human Physiology: An Integrated Approach, 8th ed. (Pearson, 2019), Ch. 20.

13. Boron, W. F. & Boulpaep, E. L., Medical Physiology, 3rd ed. (Elsevier, 2017), Ch. 36-37.

14. Rose, B. D. & Post, T. W., Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed. (McGraw-Hill, 2001).

15. Adrogué, H. J. & Madias, N. E., "Management of life-threatening acid-base disorders", N. Engl. J. Med. 338 (1998), 26-34 and 107-111.